Department of Thoracic Surgery, Weifang People's Hospital, Kuiwen District, No. 151, Guangwen Street, Weifang, Shandong, 261000, People's Republic of China.
World J Surg Oncol. 2024 Oct 9;22(1):270. doi: 10.1186/s12957-024-03545-9.
Lung cancer remains a leading cause of cancer-related mortality worldwide. Autotransplantation has emerged as a potential surgical intervention in select cases, with the aim of achieving curative outcomes. This case report describes a novel approach combining lung autotransplantation with postoperative chemotherapy and immunotherapy, delineating the patient's journey over a period of three years.
We report on a 37-year-old patient with stage IIIA non-small cell lung cancer (NSCLC) who underwent lung autotransplantation. Despite the complexity of the procedure, the patient had a favorable postoperative course. Adjuvant therapy included a PD-1 inhibitor and a standard chemotherapy regimen. The patient's follow-up involved regular clinical assessment, imaging, and functional status evaluation, demonstrating a remarkable disease-free survival at the three-year mark postoperatively.
This case highlights the potential for lung autotransplantation coupled with immunotherapy and chemotherapy to yield significant long-term survival benefits in patients with NSCLC. The favorable outcome suggests that this integrative treatment strategy warrants further investigation and may offer hope to patients with similarly advanced lung cancer.
肺癌仍然是全球癌症相关死亡的主要原因。自体移植已成为某些情况下有潜力的手术干预手段，旨在实现治愈效果。本病例报告描述了一种将肺自体移植与术后化疗和免疫治疗相结合的新方法，描述了患者三年间的治疗历程。
我们报告了一例 37 岁的 IIIA 期非小细胞肺癌（NSCLC）患者，接受了肺自体移植。尽管手术复杂，但患者术后恢复良好。辅助治疗包括 PD-1 抑制剂和标准化疗方案。患者的随访包括定期临床评估、影像学和功能状态评估，术后三年无疾病生存。
本病例强调了肺自体移植联合免疫治疗和化疗在 NSCLC 患者中获得显著长期生存获益的潜力。良好的结果表明，这种综合治疗策略值得进一步研究，并可能为具有类似晚期肺癌的患者带来希望。
